Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. 
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.



Biotechnology

Coave Therapeutics

Rodolphe Clerval

Julien Berger

Patricia Françon

Catherine Mathis

The Leadership Team at Coave Therapeutics is responsible for shaping the strategic direction of the company, overseeing the development and execution of clinical programs, and ensuring the successful advancement of novel gene therapies. This team collaborates to align research initiatives with business goals, drive operational excellence, and navigate legal and corporate matters, all while fostering innovation in the targeted delivery of gene therapies for rare ocular and CNS diseases.

Leadership Team

About

Team members

Other teams at Coave Therapeutics

Research and Development